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Introduction {#cam41052-sec-0001}
============

Although there have been enormous improvements in breast cancer diagnosis and advances in treatment, less attention has been paid to alleviating patients\' breast cancer experience by preserving their physical, functional, and psychosocial well‐being [1](#cam41052-bib-0001){ref-type="ref"}. Women with breast cancer are challenged to cope over time with a high symptom burden and distress, which affects their well‐being and quality of life [2](#cam41052-bib-0002){ref-type="ref"}, [3](#cam41052-bib-0003){ref-type="ref"}, [4](#cam41052-bib-0004){ref-type="ref"}, [5](#cam41052-bib-0005){ref-type="ref"}, [6](#cam41052-bib-0006){ref-type="ref"}, [7](#cam41052-bib-0007){ref-type="ref"}. The prevalence of mood disorders is highest in the first year after breast cancer diagnosis and then decreases gradually over time [8](#cam41052-bib-0008){ref-type="ref"}.

Still, individuals report persistent coexistent physical and psychological symptoms that contribute to interference with daily life after breast cancer treatment [9](#cam41052-bib-0009){ref-type="ref"}.

An increasing body of research has established an association between distress and changes in immune function [10](#cam41052-bib-0010){ref-type="ref"}, [11](#cam41052-bib-0011){ref-type="ref"}. Distress seems to have a significant negative effect on immune function, such as lowered natural killer cells (NK cells) and T lymphocytes (T cells) [11](#cam41052-bib-0011){ref-type="ref"}, [12](#cam41052-bib-0012){ref-type="ref"}. T cells have been linked to breast cancer recurrence and survival [13](#cam41052-bib-0013){ref-type="ref"}, [14](#cam41052-bib-0014){ref-type="ref"}, [15](#cam41052-bib-0015){ref-type="ref"}. Other important parameters are cytokines, such as interleukin‐6 (IL‐6) and interleukin‐8 (IL‐8), which are independently correlated with breast cancer disease stage and progression [16](#cam41052-bib-0016){ref-type="ref"}, [17](#cam41052-bib-0017){ref-type="ref"}, [18](#cam41052-bib-0018){ref-type="ref"}, [19](#cam41052-bib-0019){ref-type="ref"}.

Thus, previous research indicates a significant need for interventions to improve well‐being, alleviate distress and symptom burden, and to reinforce immunity in women during breast cancer diagnosis, treatment, and recovery.

Originating from ancient Buddhist and yoga traditions, mindfulness‐based interventions have become increasingly popular in the Western world. Mindfulness is described as a "way of being" and defined as the capacity for awareness in each moment, by "paying attention in a particular way: on purpose, in the present moment, and nonjudgmentally"[20](#cam41052-bib-0020){ref-type="ref"}. The use of mindfulness‐based interventions in oncology has proliferated over the past decade and research in the field has rapidly expanded [21](#cam41052-bib-0021){ref-type="ref"}, [22](#cam41052-bib-0022){ref-type="ref"} While there appears to be evidence to support the use of mindfulness‐based interventions with cancer patients, the overall quality of existing trials varies considerably [23](#cam41052-bib-0023){ref-type="ref"}.

Mindfulness‐based stress reduction (MBSR) is an 8‐week, standardized program combining mindfulness meditation, yoga and other techniques designed to reduce stress and improve well‐being and quality of life in patients with a wide range of chronic pain and stress disorders [20](#cam41052-bib-0020){ref-type="ref"}, [24](#cam41052-bib-0024){ref-type="ref"}, [25](#cam41052-bib-0025){ref-type="ref"}. MBSR and has also been shown to improve mood disorders [21](#cam41052-bib-0021){ref-type="ref"}, [26](#cam41052-bib-0026){ref-type="ref"}and reduce stress in cancer patients [27](#cam41052-bib-0027){ref-type="ref"}, [28](#cam41052-bib-0028){ref-type="ref"}. Furthermore, MBSR reduces fear of recurrence and improves physical functioning which in turn leads to reduced stress and anxiety in women with breast cancer [29](#cam41052-bib-0029){ref-type="ref"}. Evidence from nonrandomized, uncontrolled studies suggests that MBSR improves quality of life and coping, decreases stress and alters cortisol and immune patterns [30](#cam41052-bib-0030){ref-type="ref"}, [31](#cam41052-bib-0031){ref-type="ref"}, [32](#cam41052-bib-0032){ref-type="ref"}, [33](#cam41052-bib-0033){ref-type="ref"}.

These results raise important questions as to whether MBSR is related to positive outcomes in mood disorders, symptom burden and health status, as well as strengthened immune system functioning in breast cancer survivors. Despite growing evidence that MBSR influences immune function, there is a need for studies to determine how biomarkers relate to changes in mindfulness and psychosocial outcomes, including symptom reduction and well‐being [34](#cam41052-bib-0034){ref-type="ref"}. While noting the effectiveness of MBSR, authors of several reviews have pointed out the inherent methodological problems in the published studies [35](#cam41052-bib-0035){ref-type="ref"}, [36](#cam41052-bib-0036){ref-type="ref"}. There is also a need for randomized controlled studies with long‐term follow‐up [36](#cam41052-bib-0036){ref-type="ref"}.

The primary purpose of our study was to determine the efficacy of MBSR intervention for mood disorder symptom improvements in women with breast cancer. Secondary goals were to evaluate their symptom experience, distress, health status, coping capacity, mindfulness, posttraumatic growth, and immune status.

Patients and Methods {#cam41052-sec-0002}
====================

Study design {#cam41052-sec-0003}
------------

In this 3‐month follow‐up study, we present the first results of a 5‐year longitudinal, randomized, controlled trial (RTC). Details of this trial have been described elsewhere [37](#cam41052-bib-0037){ref-type="ref"}.

The trial was designed in accord with Consort recommendation [38](#cam41052-bib-0038){ref-type="ref"}, [39](#cam41052-bib-0039){ref-type="ref"}, [40](#cam41052-bib-0040){ref-type="ref"}. In an unblinded RTC, participants\' expectations about the intervention may lead to a placebo effect in the intervention group and/or a negative response among controls. In order to minimize a potential placebo effect in the active intervention group and a "frustrebo response"[41](#cam41052-bib-0041){ref-type="ref"} in controls, a three‐armed design was chosen.

Patients diagnosed with breast cancer were consecutively recruited to participate after completion of adjuvant chemotherapy and/or radiation therapy, with or without endocrine therapy. Patients were excluded on the basis of having another advanced illness at diagnosis that might interfere with the ability to participate, ongoing major depression, ongoing Herceptin therapy, or who had previously, as well as during the intervention, used MBSR and other mind‐body programs (including yoga).

This trial was approved by the Regional Ethical Review Board, University of Gothenburg, and informed consent was obtained before enrolment.

Procedures {#cam41052-sec-0004}
----------

Eligible patients were contacted by research nurses at the first follow‐up appointment for patients receiving hormonal therapy or at the last treatment for patients undergoing chemotherapy. After oral and written information, interested patients provided written consent to participate in the study. Participants were first invited to a baseline health check‐up appointment, which included blood sample collection and questionnaire completion. Randomization was computerized and conducted in blocks of 9, 12, and 15, varied randomly. Assignment codes were kept in sequentially numbered, opaque, sealed envelopes, prepared by the research coordinator.

Intervention {#cam41052-sec-0005}
------------

Participants were randomized into one of three groups:

MBSR (8 weeks self‐instructing MBSR program + instructor and weekly group sessions), active controls (8 weeks self‐instructing MBSR program) or non‐MBSR (no intervention).

Participants in the MBSR group attended a standardized, group‐based, 8‐week course once a week for an average of 2 h each week with homework assignments consisting of 20 min sessions, 6 days/week. Participants were provided with information material, including a 20‐page introduction to mindfulness training, a compacted disk (CD) with meditation exercises, the training program and a diary in order to report the time allotted to mindfulness training including patients′ reflections about the meditation exercises. Led by a certified MBSR instructor, these weekly group sessions focused on the participants\' experiences of mindfulness, and including gentle meditation and yoga training. Active controls received information material, a CD, 8 weeks of self‐instructing training program and a diary. The only difference between MBSR group and active controls was the weekly group sessions. Participants in both MBSR group and active controls were provided with written and oral instructions how to use information material, CD and diary. All participants received standard care for follow‐up for breast cancer according to the national and local guidelines [42](#cam41052-bib-0042){ref-type="ref"}.

Measures {#cam41052-sec-0006}
--------

Socio‐demographic data were collected through chart review and interviews. Clinical characteristics, patient self‐reported outcomes and biomarkers were collected at health checks both pre and postintervention. Follow‐ups for MBSR group and active controls were conducted 1 month after the intervention, and at similar time points. The same procedures, at similar time points of 3 months were conducted for those in the non‐MBSR group.

Primary outcome measures {#cam41052-sec-0007}
------------------------

### Mood disorder {#cam41052-sec-0008}

Mood disorder was measured using the Hospital Anxiety and Depression scale (HAD), which is one of most widely used instruments to screen for anxiety and depression in cancer patients [43](#cam41052-bib-0043){ref-type="ref"}, [44](#cam41052-bib-0044){ref-type="ref"}, [45](#cam41052-bib-0045){ref-type="ref"}. The HAD is a 14‐item questionnaire consisting of two subscales: anxiety and depression. Subscale scores range from 0 to 21; scores for each subscale are defined as: 0--7 (normal), 8--10 (possible cases), and 11--21 (cases of psychological morbidity) [46](#cam41052-bib-0046){ref-type="ref"}. The internal consistency of reliability for both subscales are satisfactory, with Cronbach\'s alpha 0.72--0.89, respectively, 0.78--0.93 [45](#cam41052-bib-0045){ref-type="ref"}

Secondary outcomes measures {#cam41052-sec-0009}
---------------------------

### Symptom experience {#cam41052-sec-0010}

Symptom experience was evaluated using the Memorial Symptom Assessment Scale (MSAS), a questionnaire consisting of 32 symptoms and symptom frequency, severity, and distress [47](#cam41052-bib-0047){ref-type="ref"}. The MSAS generates two subscales including physical and psychological symptoms, and two global indicators: Total Symptom Burden Scale (TMSAS) and the Global Symptom Distress Index (GDI). The MSAS is a reliable and valid multidimensional measure of symptom experience in cancer populations [47](#cam41052-bib-0047){ref-type="ref"}, [48](#cam41052-bib-0048){ref-type="ref"} including the Swedish version of the MSAS [49](#cam41052-bib-0049){ref-type="ref"}.

### Health status {#cam41052-sec-0011}

Health status was measured using the 36‐item Short Form Health Survey (SF‐36), which consists of eight scaled scores: vitality, physical functioning, bodily pain, general health perceptions, physical, emotional and social role functioning, and mental health. The maximum score is 100 points. Reliability measurements of the SF‐36 are consistently good [50](#cam41052-bib-0050){ref-type="ref"}, [51](#cam41052-bib-0051){ref-type="ref"}, [52](#cam41052-bib-0052){ref-type="ref"}, [53](#cam41052-bib-0053){ref-type="ref"}.

### Coping capacity {#cam41052-sec-0012}

Coping capacity was evaluated using the Sense of Coherence scale (SOC) [54](#cam41052-bib-0054){ref-type="ref"}, [55](#cam41052-bib-0055){ref-type="ref"}, which consists of a 7‐point Likert scale evaluating perceived comprehensibility (5 items), manageability (4 items) and meaningfulness (4 items). Higher scores represent stronger sense of coherence. Reliability and validity of the SOC scale have been demonstrated, with Cronbach\'s *α* ranging from 0.74 to 0.93 [56](#cam41052-bib-0056){ref-type="ref"}, [57](#cam41052-bib-0057){ref-type="ref"}, [58](#cam41052-bib-0058){ref-type="ref"}.

### Mindfulness {#cam41052-sec-0013}

Mindfulness was measured using the 29‐item short form Five Facets of Mindfulness Questionnaire (FFMQ--Swedish version), consisting of five key facets of mindfulness: observing, describing, acting with awareness, nonjudging, and nonreactivity to inner experience [59](#cam41052-bib-0059){ref-type="ref"}, [60](#cam41052-bib-0060){ref-type="ref"}.

### Personal growth {#cam41052-sec-0014}

Personal growth was evaluated using the Posttraumatic Growth Inventory (PTGI), which measures positive life changes after traumatic events. The PTGI yields a total score based on five dimensions: relating to others, new possibilities, personal strength, spiritual change, and appreciation of life [61](#cam41052-bib-0061){ref-type="ref"}. The PTGI has shown good reliability in previous research with a total score Cronbach\'s *α* of 0.96 [62](#cam41052-bib-0062){ref-type="ref"}.

### Lymphocyte distribution in peripheral blood {#cam41052-sec-0015}

Lymphocyte distribution in peripheral blood was analyzed by flow cytometry using a FACSCanto II flow cytometer and the FACSDiva software. The absolute number of blood lymphocytes was determined with Trucount reference beads using the method recommended by the manufacturer. The following subpopulations were reported CD3^+^, CD3^+^4^+^ and CD3^+^8^+^T cells, CD19^+^B cells, and CD3‐16^+^56^+^NK cells. The results for each subpopulation were expressed as the percentage of lymphocytes and as the number of cells × 10^9^/L. Antibodies to the antigens above. Trucount beads, the FACSCanto II flow cytometer and the FACSDiva software were all from BD Biosciences, Mountain View, CA.

### NK‐cell activity {#cam41052-sec-0016}

NK‐cell activity was measured using a Flow‐cytometric Assay of Natural Killer cell Immune response in Activated whole blood (FANKIA) a modified version of a previously published method using flow cytometry and stained K562 cells as target cells [63](#cam41052-bib-0063){ref-type="ref"}. Whole blood was mixed with a defined number of target cells transfected with the gene for green fluorescent protein (GFP) [64](#cam41052-bib-0064){ref-type="ref"}. After incubation the same volume was collected from tubes with: blood and target cells, target cells and medium; and blood and medium and analyses were performed as described above. The lytic activity was defined as the reduction in the number of target cells after mixing with the blood, expressed in percentage of target cells.

### Determination of cytokine concentrations {#cam41052-sec-0017}

Determination of cytokine concentrations were determined in sera using commercial high sensitivity IL‐6 and IL‐8 ELISA kits (R&D Systems, Inc., Abingdon, UK) according to the instructions from the manufacturer.

Data analysis {#cam41052-sec-0018}
-------------

Sample size calculation was based on the primary outcome: breast cancer patient\'s mood disorder symptoms. A one‐unit change on the HAD‐subscales from baseline to 3‐month follow‐up was regarded as clinically relevant. The detection of such a difference would require 50 participants per group (a total of 150 participants) to achieve a statistical power of 80%. Descriptive statistics were used to summarize socio‐demographic and clinical characteristics. Spearman\'s correlation coefficients were calculated to determine the strength of relationships between selected variables. As most of the variables we explored were of ordinal data type and most of the continuous variables deal with skewed distributions deviating from normal‐distribution, we used nonparametric tests (Wilcoxon\'s test for comparison within groups and Mann--Whitney\'s test for comparison between groups).

*P* \< 0.05 was considered as statistically significant result.

Results {#cam41052-sec-0019}
=======

A total of 177 women consented participation and were randomly assigned to one of three groups. There were 11 drop‐outs after randomization, that is, two patients were excluded as they did not complete the intervention, two patients withdraw their participation due to rapid breast cancer disease progression, and seven patients did not visited first follow‐up (MBSR* *=* *4; active controls* *=* *5; non‐MBSR* *=* *2).

The final groups were MBSR (*n *=* *62), active controls (*n *=* *52) and non‐MBSR (*n *=* *52). Postintervention data were missing for one active control participant. A participation flowchart is depicted in Figure [1](#cam41052-fig-0001){ref-type="fig"}.

![Flowchart of study design and randomization.](CAM4-6-1108-g001){#cam41052-fig-0001}

Participants\' ranged from 34 to 80 years (mean* *=* *57.2, SD* *=* *10.2). No statistical differences were found between groups on demographic or clinical characteristics. Participant descriptions are listed in Table [1](#cam41052-tbl-0001){ref-type="table-wrap"}.

###### 

Baseline demographic data and clinical characteristics

  Characteristic                                                  MBSR group (*n* = 62)   Active controls (*n* = 52)   Non‐MBSR (*n* = 52)   Total (*n* = 166)                      
  --------------------------------------------------------------- ----------------------- ---------------------------- --------------------- ------------------- ----- ------ ----- ------
  Marital status                                                                                                                                                                    
  Married/cohabitation                                            46                      74.2                         35                    67.3                42    80.8   123   74.1
  Widowed                                                         3                       4.8                          3                     5.8                 4     7.7    10    6.0
  Divorced                                                        6                       9.7                          8                     15.4                1     1.9    15    9.0
  Single                                                          5                       8.1                          4                     7.7                 4     7.7    13    7.8
  Partner without l.t.[a](#cam41052-note-0004){ref-type="fn"}     2                       3.2                          2                     3.8                 1     1.9    5     3.0
  Living with                                                                                                                                                                       
  Partner                                                         44                      71.0                         35                    67.3                41    78.8   120   72.3
  Other                                                           1                       1.6                          0                     0                   1     1.9    2     1.2
  Children                                                        7                       11.3                         2                     3.8                 2     3.8    11    6.6
  Living alone                                                    10                      16.1                         15                    28.8                8     15.4   33    19.9
  Education                                                                                                                                                                         
  Primary school                                                  5                       8.1                          1                     1.9                 1     1.9    7     4.2
  Secondary school                                                14                      22.6                         10                    19.2                11    21.2   35    21.1
  Add education--lower[b](#cam41052-note-0005){ref-type="fn"}     6                       9.7                          6                     11.5                10    19.2   22    13.3
  Add education-- higher[c](#cam41052-note-0006){ref-type="fn"}   7                       11.3                         11                    21.2                5     9.6    23    13.9
  University                                                      30                      48.4                         24                    46.2                25    48.1   79    47.6
  Children                                                                                                                                                                          
  Yes                                                             57                      91.9                         49                    94.2                45    86.5   151   91.0
  No                                                              5                       8.1                          3                     5.8                 7     13.5   15    9.0
  Employment status                                                                                                                                                                 
  Working                                                         38                      63.3                         38                    74.5                35    68.6   111   68.5
  Unemployed                                                      1                       1.7                          0                     0                   0     0      1     0.6
  Disability pensioner                                            2                       3.3                          3                     5.9                 1     2.0    6     3.7
  Retired                                                         18                      30.0                         10                    19.6                15    29.4   43    26.5
  Other                                                           1                       1.7                          0                     0                   0     0      1     0.6
  Surgery                                                                                                                                                                           
  Mastectomy                                                      30                      48.4                         26                    50.0                21    40.4   77    46.4
  Lumpectomy                                                      33\*                    53.2                         26                    50.0                30    57.7   89    53.6
  Other                                                           0                       0                            0                     0                   1     1.9    1     0.6
  Tumor size                                                                                                                                                                        
  \<2 cm                                                          28                      45.9                         25                    49.0                32    64.0   85    52.5
  2--5 cm                                                         25                      41.0                         22                    43.1                8     16.0   55    34.0
  \>5 cm                                                          8                       13.1                         4                     7.8                 10    20.0   22    13.6
  Type of cancer                                                                                                                                                                    
  Ductal                                                          43                      69.4                         37                    71.2                40    76.9   120   72.3
  Lobular                                                         13                      21.0                         9                     17.3                6     11.5   28    16.9
  Other                                                           6                       9.7                          6                     11.5                6     11.5   18    10.8
  Receptor                                                                                                                                                                          
  ER+/PgR+                                                        40                      69.0                         34                    72.3                39    78.0   113   72.9
  ER+/PgR‐                                                        8                       13.8                         6                     12.8                4     8.0    17    11.6
  ER‐/PgR+                                                        0                       0.0                          0                     0.0                 1     2.0    1     0.6
  ER‐/PgR‐                                                        10                      17.2                         7                     14.9                6     12.0   24    14.8
  BRE (mean)                                                      6.6                                                  6.5                                       6.6                
  Treatment postop                                                                                                                                                                  
  Chemotherapy (CT)                                               2                       3.2                          3                     5.8                 3     5.8          
  Radiotherapy (RT)                                               3                       4.8                          5                     9.6                 4     7.7          
  Hormonal therapy (HT)                                           12                      19.4                         14                    26.9                6     11.5         
  CT+RT                                                           11                      17.8                         6                     11.5                7     13.5         
  CT+ HT                                                          4                       6.5                          0                     0                   1     1.9          
  RT+ HT                                                          16                      25.8                         13                    25.0                16    30.8         
  CT+RT+HT                                                        13                      20.9                         10                    19.2                14    26.9         
  No treatment                                                    1                       1.6                          1                     1.9                 1     1.9          

ER, estrogen receptor; PgR, progesterone receptor.

Partner, not living together with.

Lower additional education.

Higher additional education.
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Psychological response {#cam41052-sec-0020}
----------------------

Study results revealed significant changes in psychological and biological responses to the MBSR intervention, summarized in Tables [2](#cam41052-tbl-0002){ref-type="table-wrap"}, [3](#cam41052-tbl-0003){ref-type="table-wrap"}, [4](#cam41052-tbl-0004){ref-type="table-wrap"}, [5](#cam41052-tbl-0005){ref-type="table-wrap"}, [6](#cam41052-tbl-0006){ref-type="table-wrap"}, [7](#cam41052-tbl-0007){ref-type="table-wrap"}, [8](#cam41052-tbl-0008){ref-type="table-wrap"}.

###### 

Primary outcome: pre and postintervention mood disorder symptoms

  Measures HAD[a](#cam41052-note-0007){ref-type="fn"}   Group       Preintervention   Postintervention   *P*‐value[b](#cam41052-note-0008){ref-type="fn"}   *P*‐value[c](#cam41052-note-0009){ref-type="fn"}                                                       
  ----------------------------------------------------- ----------- ----------------- ------------------ -------------------------------------------------- -------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Anxiety                                               MBSR        6.5 (4.3)         6 (0--19)          6.0 (3.9)                                          6 (0--16)                                          0.069                                               0.080
  Active Controls                                       5.6 (3.9)   4.5 (0--14)       5.1 (3.9)          5 (0--13)                                          0.236                                              0.109                                               
  Non‐MBSR                                              4.8 (3.6)   4.5 (0--12)       5.5 (4.1)          5 (0--15)                                          0.355                                              Ref.                                                
  Depression                                            MBSR        4.3 (3.7)         4 (0--14)          3.3 (3.3)                                          2 (0--12)                                          **0.001** [a](#cam41052-note-0007){ref-type="fn"}   **0.015** [a](#cam41052-note-0007){ref-type="fn"}
  Active Controls                                       3.4 (3.4)   2 (0--14)         3.0 (2.9)          2 (0--12)                                          0.292                                              0.472                                               
  Non‐MBSR                                              3.5 (3.5)   2 (0--14)         3.8 (3.8)          2 (0--15)                                          0.892                                              Ref.                                                

Significant changes are marked in bold.

The Hospital Anxiety and Depression Scale (HAD).

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).

John Wiley & Sons, Ltd

###### 

Secondary outcome: symptom experience

  Measure MSAS[a](#cam41052-note-0010){ref-type="fn"}   Group       Preintervention   Postintervention   *P‐*value[b](#cam41052-note-0011){ref-type="fn"}   *P*‐value[c](#cam41052-note-0012){ref-type="fn"}                                                       
  ----------------------------------------------------- ----------- ----------------- ------------------ -------------------------------------------------- -------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Physical symptoms                                     MBSR        0.7 (0.5)         0.61 (0--2.30)     0.6 (0.4)                                          0.52 (0--2.15)                                     **0.007** [a](#cam41052-note-0010){ref-type="fn"}   0.245
  Active controls                                       0.5 (0.4)   0.49 (0--1.45)    0.5 (0.4)          0.41 (0--2.13)                                     0.372                                              0.966                                               
  Non‐MBSR                                              0.6 (0.5)   0.46 (0--2.11)    0.5 (0.5)          0.45 (0--2.34)                                     0.475                                              Ref.                                                
  Psychological symptoms                                MBSR        1.4 (0.8)         1.34 (0--3.22)     1.2 (0.9)                                          0.98 (0--3.32)                                     **0.008** [a](#cam41052-note-0010){ref-type="fn"}   **0.019** [a](#cam41052-note-0010){ref-type="fn"}
  Active controls                                       1.0 (0.9)   0.77 (0--2.77)    0.9 (0.8)          0.69 (0--2.67)                                     0.335                                              0.337                                               
  Non‐MBSR                                              0.9 (0.8)   0.76 (0--2.92)    0.9 (0.8)          0.83 (0--2.82)                                     0.800                                              Ref.                                                
  Global distress                                       MBSR        1.9 (0.6)         1.93 (0--2.97)     1.8 (0.6)                                          1.80 (0--3.05)                                     0.054                                               **0.013** [a](#cam41052-note-0010){ref-type="fn"}
  Active controls                                       1.7 (0.8)   1.80 (0--3.24)    1.6 (0.8)          1.60 (0--3.20)                                     0.121                                              **0.015** [a](#cam41052-note-0010){ref-type="fn"}   
  Non‐MBSR                                              1.6 (0.8)   1.79 (0--4.0)     1.7 (0.9)          2.0 (0--3.2)                                       0.103                                              Ref.                                                
  Total symptom burden                                  MBSR        0.8 (0.5)         0.71 (0--2.13)     0.7 (0.5)                                          0.55 (0--2.22)                                     **0.004** [a](#cam41052-note-0010){ref-type="fn"}   0.097
  Active controls                                       0.6 (0.4)   0.56 (0--1.52)    0.5 (0.3)          0.49 (0--1.5)                                      0.113                                              0.671                                               
  Non‐MBSR                                              0.6 (0.4)   0.54 (0--1.59)    0.6 (0.4)          0.56 (0.05--2.0)                                   0.379                                              Ref.                                                
                                                                                                                                                                                                                                                                   

Significant changes are marked in bold.

MSAS, Memorial Symptom Assessment Scale.

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).
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###### 

Secondary outcome: health status

  Measure SF‐36[a](#cam41052-note-0013){ref-type="fn"}   Group         Preintervention   Postintervention   *P*‐value[b](#cam41052-note-0014){ref-type="fn"}   *P*‐value[c](#cam41052-note-0015){ref-type="fn"}                                                        
  ------------------------------------------------------ ------------- ----------------- ------------------ -------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Vitality                                               MBSR          49.5 (27.5)       52.5 (29--75)      60.9 (20.1)                                        65 (45--76)                                         **0.000** [a](#cam41052-note-0013){ref-type="fn"}   0.159
  Active Controls                                        56.9 (24.4)   60 (40--75)       62.5 (23.7)        65 (45--80)                                        0.129                                               0.838                                               
  Non‐MBSR                                               55.0 (25.8)   55 (40--80)       58.3 (24.4)        60 (35--80)                                        0.397                                               Ref.                                                
  Physical functioning                                   MBSR          77.4 (16.7)       80 (67.5--90)      83.1 (15.4)                                        90 (75--95)                                         **0.000** [a](#cam41052-note-0013){ref-type="fn"}   0.822
  Active Controls                                        83.7 (17.3)   90 (75--95)       84.8 (18.5)        95 (80--95)                                        0.412                                               0.129                                               
  Non‐MBSR                                               78.5 (19.6)   80 (70--95)       82.8 (19.0)        90 (71.0--95)                                      **0.007** [a](#cam41052-note-0013){ref-type="fn"}   Ref.                                                
  Bodily pain                                            MBSR          65.2 (26.4)       67 (45--90)        71.4 (23.5)                                        77.5 (45--92)                                       0.099                                               0.799
  Active Controls                                        70.9 (20.7)   77.5 (55--90)     74.4 (25.2)        79.5 (57--100)                                     0.466                                               0.526                                               
  Non‐MBSR                                               70 (23.1)     67 (56--90)       73.5 (27.1)        85 (56--100)                                       0.253                                               Ref.                                                
  General health perceptions                             MBSR          61.2 (21.6)       60 (45--75)        67.6 (19.1)                                        70 (52--85)                                         **0.003** [a](#cam41052-note-0013){ref-type="fn"}   0.087
  Active Controls                                        67.2 (19.3)   75 (55--80)       70.6 (19.1)        70 (60--85)                                        0.111                                               0.465                                               
  Non‐MBSR                                               69.3 (19.4)   70 (60--85)       69.6 (19.6)        75 (55--80)                                        0.832                                               Ref.                                                
  Physical role functioning                              MBSR          45.9 (42.9)       50 (0--100)        63.3 (39.7)                                        75 (25--100)                                        **0.003** [a](#cam41052-note-0013){ref-type="fn"}   0.822
  Active Controls                                        42.2 (42.6)   25 (0--100)       67.6 (35.8)        75 (50--100)                                       **0.001** [a](#cam41052-note-0013){ref-type="fn"}   0.463                                               
  Non‐MBSR                                               40.4 (41.5)   25 (0--75)        59.6 (42.3)        75 (6--100)                                        **0.006** [a](#cam41052-note-0013){ref-type="fn"}   Ref.                                                
  Emotional role functioning                             MBSR          61.7 (41.2)       67 (33--100)       72.1 (38.6)                                        100 (33--100)                                       0.053                                               0.900
  Active Controls                                        69.9 (38.5)   100 (33--100)     77.1 (35.6)        100 (67--100)                                      0.168                                               0.652                                               
  Non‐MBSR                                               60.9 (47.0)   100 (0--100)      72.4 (37.2)        100 (33--100)                                      0.093                                               Ref.                                                
  Social functioning                                     MBSR          74.0 (23.0)       75 (62--100)       79.0 (20.7)                                        87.5 (62--100)                                      0.103                                               0.117
  Active Controls                                        78.4 (25.9)   87.5 (62--100)    84.8 (22.8)        100 (62--100)                                      **0.017** [a](#cam41052-note-0013){ref-type="fn"}   0.105                                               
  Non‐MBSR                                               72.1 (26.0)   75 (50--100)      84.1 (25.3)        100 (75--100)                                      **0.001** [a](#cam41052-note-0013){ref-type="fn"}   Ref.                                                
  Mental health                                          MBSR          67.9 (19.0)       72 (56--80)        74.1 (17.1)                                        76 (64--85)                                         **0.000** [a](#cam41052-note-0013){ref-type="fn"}   **0.001** [a](#cam41052-note-0013){ref-type="fn"}
  Active Controls                                        73.5 (22.7)   80 (60--92)       77.8 (17.4)        80 (64--92)                                        0.073                                               **0.038** [a](#cam41052-note-0013){ref-type="fn"}   
  Non‐MBSR                                               76.2 (20.0)   84 (64--88)       74.4 (20.7)        84 (60--92)                                        0.299                                               Ref.                                                

Significant changes are marked in bold.

36‐items short form health survey (SF‐36).

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).
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###### 

Secondary outcome: coping capacity

  Measure SoC[a](#cam41052-note-0016){ref-type="fn"}   Group         Preintervention   Postintervention   *P*‐value[b](#cam41052-note-0017){ref-type="fn"}   *P*‐value[c](#cam41052-note-0018){ref-type="fn"}           
  ---------------------------------------------------- ------------- ----------------- ------------------ -------------------------------------------------- -------------------------------------------------- ------- ---------------------------------------------------
  Coping capacity                                      MBSR          65.7 (13.7)       67 (32--91)        67.7 (12.0)                                        66.5 (39--91)                                      0.055   **0.028** [a](#cam41052-note-0016){ref-type="fn"}
  Active controls                                      69.8 (13.7)   71 (28--90)       70.8 (12.5)        75 (41--90)                                        0.458                                              0.098   
  Non‐MBSR                                             71.4 (11.1)   72 (39--88)       69.3 (11.5)        69 (45--87)                                        0.113                                              Ref.    

Significant changes are marked in bold.

SoC, Sense of Coherence.

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).
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###### 

Secondary outcome: facets of mindfulness

  Measure FFMQ[a](#cam41052-note-0019){ref-type="fn"}   Group       Preintervention   Postintervention   *P*‐value[b](#cam41052-note-0020){ref-type="fn"}   *P*‐value[c](#cam41052-note-0021){ref-type="fn"}                                                        
  ----------------------------------------------------- ----------- ----------------- ------------------ -------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Nonreactivity                                         MBSR        2.9 (0.7)         3.0 (1.3--4.5)     3.3 (0.5)                                          3.2 (2.0--4.7)                                      **0.000** [a](#cam41052-note-0019){ref-type="fn"}   **0.010** [a](#cam41052-note-0019){ref-type="fn"}
  Active Controls                                       3.2 (0.6)   3.2 (1.8--4.3)    3.3 (0.5)          3.3 (1.8--4.3)                                     0.318                                               0.759                                               
  Non‐MBSR                                              3.1 (0.6)   3.2 (1.0--4.3)    3.2 (0.7)          3.2 (1.0--4.3)                                     0.552                                               Ref.                                                
  Observe                                               MBSR        3.3 (0.7)         3.3 (1.0--4.7)     3.6 (0.5)                                          3.7 (1.7--4.9)                                      **0.000** [a](#cam41052-note-0019){ref-type="fn"}   **0.006** [a](#cam41052-note-0019){ref-type="fn"}
  Active Controls                                       3.3 (0.7)   3.3 (1.4--4.9)    3.4 (0.7)          3.4 (1.4--5.0)                                     **0.015** [a](#cam41052-note-0019){ref-type="fn"}   0.376                                               
  Non‐MBSR                                              3.1 (0.7)   3.1 (1.6--4.1)    3.2 (0.7)          3.3 (1.0--4.6)                                     0.190                                               Ref.                                                
  Awareness                                             MBSR        3.3 (0.8)         3.4 (1.8--5.0)     3.3 (0.6)                                          3.2 (2.0--5.0)                                      0.751                                               0.783
  Active Controls                                       3.5 (0.8)   3.6 (1.8--5.0)    3.4 (0.7)          3.4 (2.0--5.0)                                     0.280                                               0.224                                               
  Non‐MBSR                                              3.4 (0.7)   3.3 (1.8--4.8)    3.4 (0.8)          3.3 (2.0--5.0)                                     0.984                                               Ref.                                                
  Describe                                              MBSR        3.6 (0.7)         3.7 (2.0--5.0)     3.6 (0.6)                                          3.8 (2.0--4.7)                                      0.599                                               0.478
  Active Controls                                       3.6 (0.6)   3.7 (2.0--4.8)    3.6 (0.7)          3.7 (2.0--5.0)                                     0.938                                               0.700                                               
  Non‐MBSR                                              3.5 (0.7)   3.7 (1.8--5.0)    3.5 (0.8)          3.6 (1.0--5.0)                                     0.659                                               Ref.                                                
  Nonjudge                                              MBSR        3.3 (0.8)         3.4 (1.2--5.0)     3.3 (0.8)                                          3.2 (1.6--5.0)                                      0.992                                               0.361
  Active Controls                                       3.5 (0.8)   3.4 (2.0--5.0)    3.4 (0.7)          3.4 (2.4--5.0)                                     0.339                                               0.775                                               
  Non‐MBSR                                              3.7 (0.8)   3.6 (2.0--5.0)    3.5 (0.9)          3.6 (1.8--5.0)                                     0.164                                               Ref.                                                

Significant changes are marked in bold.

FFMQ, Five Facets of Mindfulness Questionnaire.

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).
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###### 

Secondary outcome: Posttraumatic Growth

  Measure PTGI[a](#cam41052-note-0022){ref-type="fn"}   Group          Preintervention   Postintervention   *P*‐value[b](#cam41052-note-0023){ref-type="fn"}   *P*‐value[c](#cam41052-note-0024){ref-type="fn"}               
  ----------------------------------------------------- -------------- ----------------- ------------------ -------------------------------------------------- -------------------------------------------------- ----------- -------
  Posttraumatic growth                                  MBSR           59.78 (19.5)      62.00 (17--103)    64.65 (17.7)                                       67.00 (6--100)                                     **0.005**   0.111
  Active Controls                                       55.92 (20.2)   58.50 (0--92)     57.13 (17.6)       61.00 (17--89)                                     0.498                                              **0.049**   
  Non‐MBSR                                              52.58 (19.2)   55.50 (13--85)    51.57 (20.8)       52.00 (0--94)                                      0.933                                              Ref.        

Significant changes are marked in bold.

PTGI, Posttraumatic Growth Inventory.

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).
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###### 

Secondary outcome: immune response

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Measures                  Group         Preintervention     Postintervention   *P*‐value[a](#cam41052-note-0025){ref-type="fn"}   *P*‐value[b](#cam41052-note-0026){ref-type="fn"}               
  ------------------------- ------------- ------------------- ------------------ -------------------------------------------------- -------------------------------------------------- ----------- -----------
  Fankia%                   MBSR          19.1 (8.2)          18 (14--25)        22.0 (7.7)                                         22 (17--27)                                        **0.015**   0.142

  Active Controls           22.0 (7.6)    20 (14.5--26.5)     18.8 (7.3)         19 (16--23)                                        0.668                                              0.602       

  Non‐MBSR                  19.2 (8.4)    19 (13--24)         19.6 (6.8)         20 (15--25)                                        0.731                                              Ref         

  Lymphocytesx10e9/I        MBSR          1.5 (0.76)          1.3 (0.98--1.7)    1.4 (0.58)                                         1.4 (0.98--1.7)                                    0.997       0.559

  Active Controls           1.6 (0.7)     1.4 (1.2--1.9)      1.5 (0.5)          1.4 (1.1--1.7)                                     0.415                                              0.280       

  Non‐MBSR                  1.4 (0.6)     1.3 (0.96--1.7)     1.4 (0.6)          1.2 (0.97--1.8)                                    0.518                                              Ref         

  CD3T%                     MBSR          72.8 (11.1)         74 (66.7--82.0)    71.4 (10.5)                                        72 (67--80)                                        **0.027**   0.222

  Active Controls           72.9 (7.5)    71 (68--78)         71.5 (7.7)         71 (68--77)                                        0.289                                              0.061       

  Non‐MBSR                  76.3 (8.1)    78 (71--82)         73.4 (8.8)         75 (67--79)                                        **0.001**                                          Ref         

  CD3Tx10e9/I               MBSR          1.1 (0.6)           0.97 (0.67--1.3)   1.0 (0.5)                                          1.0 (0.63--1.3)                                    0.671       0.800

  Active Controls           1.2 (0.6)     1.1 (0.8--1.4)      1.1 (0.4)          1.0 (0.7--1.2)                                     0.263                                              0.424       

  Non‐MBSR                  1.0 (0.4)     1 (0.8--1.3)        1.0 (0.5)          0.8 (0.7--1.3)                                     0.937                                              Ref         

  CD3^+^4^+^Th%             MBSR          41.7 (8.7)          42 (37--48)        41.1 (8.7)                                         40.5 (35--47)                                      0.274       0.253

  Active Controls           44.9 (8.1)    46 (39--50)         44.5 (8.4)         45 (41--50)                                        0.987                                              0.080       

  Non‐MBSR                  46.2 (9.8)    46 (38--55)         44.3 (9.1)         43.5 (39--50)                                      **0.021**                                          Ref         

  CD3^+^4^+^x10e9/I         MBSR          0.62 (0.31)         0.54 (0.4--0.7)    0.60 (0.29)                                        0.53 (0.4--0.7)                                    0.581       0.860

  Active Controls           0.73 (0.4)    0.69 (0.5--0.8)     0.66 (0.3)         0.65 (0.4--0.8)                                    0.543                                              0.864       

  Non‐MBSR                  0.63 (0.28)   0.62 (0.4--0.8)     0.62 (0.31)        0.56 (0.4--0.7)                                    0.834                                              Ref         

  CD3^+^8^+^T cy/s%         MBSR          29.6 (11.3)         28 (20--37)        28.4 (10.5)                                        25.5 (20--38)                                      **0.035**   1.00

  Active Controls           27.9 (10.4)   26 (21--35)         26.7 (9.5)         25 (20--34)                                        **0.041**                                          0.819       

  Non‐MBSR                  28.6 (11.2)   25 (21--38)         27.8 (11.7)        24.5 (19--36)                                      0.132                                              Ref         

  CD3^+^8^+^x10e9/I         MBSR          0.46 (0.33)         0.37 (0.2--0.6)    0.42 (0.26)                                        0.33 (0.2--0.6)                                    0.658       0.750

  Active Controls           0.44 (0.26)   0.38 (0.3--0.6)     0.38 (0.18)        0.34 (0.23--0.5)                                   0.144                                              0.384       

  Non‐MBSR                  0.40 (0.27)   0.32 (0.2--0.5)     0.41 (0.30)        0.28 (0.2--0.5)                                    0.655                                              Ref         

  CD3‐16^+^56^+^NK%         MBSR          16.7 (8.1)          14.5 (11--21)      16.1 (7.5)                                         15 (10--21)                                        0.329       0.077

  Active Controls           15.9 (6.1)    15 (12--20)         15.2 (6.2)         15 (11--19)                                        0.057                                              **0.025**   

  Non‐MBSR                  14.8 (6.2)    13.5 (10--19)       15.7 (7.1)         15.5 (10--18)                                      0.127                                              Ref         

  CD3‐16^+^56^+^NKx10e9/I   MBSR          0.24 (0.16)         0.2 0.1--0.3)      0.22 (0.10)                                        0.2 (0.1--0.3)                                     0.239       **0.041**

  Active Controls           0.25 (0.14)   0.24 (0.1--0.3)     0.22 (0.13)        0.19 (0.1--0.3)                                    0.121                                              **0.011**   

  Non‐MBSR                  0.20 (0.11)   0.17 (0.1--0.3)     0.22 (0.13)        0.18 (0.1--0.3)                                    0.051                                              Ref         

  CD19B%                    MBSR          9.5 (8.4)           7.5 (3.7--13)      11.6 (7.6)                                         10 (7--14)                                         **0.001**   0.957

  Active Controls           10.2 (4.8)    10 (7--13)          12.2 (5.5)         12 (9--15)                                         **0.007**                                          0.417       

  Non‐MBSR                  7.7 (5.4)     8 (3--11)           9.8 (4.7)          9 (6--12)                                          **0.003**                                          Ref         

  CD19Bx10e9/I              MBSR          0.15 (0.16)         0.1 (0.04--0.21)   0.17 (0.15)                                        0.1 (0.08--0.21)                                   **0.004**   0.862

  Active Controls           0.17 (0.12)   0.14 (0.08--0.23)   0.17 (0.09)        0.17 (0.11--0.22)                                  0.385                                              0.362       

  Non‐MBSR                  0.11 (0.08)   0.1 (0.03--0.16)    0.13 (0.07)        0.13 (0.09--0.17)                                  **0.013**                                          Ref         

  CD3+4+/CD3+8+quotient%    MBSR          1.65 (0.73)         1.6 1--2.2)        1.72 (0.82)                                        1.6 (1--2.2)                                       0.220       0.313

  Active Controls           1.92 (0.99)   1.7 (1.2--2.3)      1.99 (1.1)         1.8 (1.2--2.3)                                     0.272                                              0.336       

  Non‐MBSR                  1.98 (1.2)    1.7 (1.1--2.6)      2.06 (1.7)         1.8 (1.1--2.5)                                     0.812                                              Ref         

  IL6‐HS\                   MBSR                              1.0 (0.7--2.3)                                                        1.0 (0.6--1.7)                                     0.750       0.847
  (ELISA)                                                                                                                                                                                          

  Active Controls                         1.2 (0.7--1.7)                         1.0 (0.7--2.1)                                     0.983                                              0.528       

  Non‐MBSR                                1.1 (0.5--2.5)                         1.2 (0.5--1.8)                                     0.291                                              Ref.        

  IL8‐HS\                   MBSR                              11.5 (9.3--5)                                                         12.0 (9.7--15.7)                                   0.241       0.395
  (ELISA)                                                                                                                                                                                          

  Active Controls                         12.0 (9.0--4)                          12.0 (9.4--15.0)                                   1.000                                              0.595       

  Non‐MBSR                                12.0 (9.0--5)                          12.0 (9.3--16.0)                                   0.894                                              Ref.        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant changes are marked in bold.

Change over time (*P*‐value) within groups (Wilcoxon signed test).

Change over time (*P*‐value) between groups (comparison of MBSR‐Active controls vs. Non‐MBSR (ref.) (Mann--Whitney test).
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On the primary outcome measures, MBSR participants reported significant improvements on depression symptoms both within group (mean* *=* *4.3; SD* *=* *3.7 to mean* *=* *3.3; SD* *=* *3.3; *P *=* *0.001) as well as compared to non‐MBSR (*P *=* *0.015**)**, but not on anxiety symptoms (Table [2](#cam41052-tbl-0002){ref-type="table-wrap"}).

The number of reduced cases of depression were 7 (11%) in MBSR participants compared to 4 (8%) reduced cases of depression in active controls and non‐MBSR, respectively.

Pre and postintervention HAD scores for depression and anxiety are presented in Figure [2](#cam41052-fig-0002){ref-type="fig"}.

![Box‐plot. Primary outcome: Pre and Postintervention Mood Disorder Symptoms, HAD scores for depression, respectively, anxiety subscales.](CAM4-6-1108-g002){#cam41052-fig-0002}

There were significant improvements in physical symptoms (mean* *=* *0.7; SD* *=* *0.5 to mean* *=* *0.6; SD* *=* *0.4; *P *=* *0.007), psychological symptoms (mean* *=* *1.4; SD* *=* *0.8; to mean* *=* *1.2; SD* *=* *0.9; *P *=* *0.008), and total symptom burden (mean* *=* *0.8; SD* *=* *0.5 to mean* *=* *0.7; SD* *=* *0.5; *P *=* *0.004) within the MBSR. There were also significant improvements between MBSR versus non‐MBSR regarding psychological symptoms (*P *=* *0.019), as well as global distress (*P *=* *0.013) (Table [3](#cam41052-tbl-0003){ref-type="table-wrap"}).

Within the MBSR group, changes in health status were seen in improved vitality (mean* *=* *49.5; SD* *=* *27.5 to mean* *=* *60.9; SD* *=* *20.1; *P *\<* *0.001), physical functioning (mean* *=* *77.4; SD* *=* *16.7 to mean* *=* *83.1; SD* *=* *15.4; *P *\<* *0.001), general health perceptions (mean* *=* *61.2; SD* *=* *21.6 to mean* *=* *67.6; SD* *=* *19.1; *P *=* *0.003), physical role functioning (mean* *=* *45.9; SD* *=* *42.9 to mean* *=* *63.3; SD* *=* *39.7; *P *=* *0.003), and mental health (mean* *=* *67.9; SD* *=* *19.0 to mean* *=* *74.1; SD* *=* *17.1; *P *\<* *0.001). Changes were reported in physical functioning within the non‐MBSR group (mean* *=* *78.5; SD* *=* *19.6 to mean* *=* *82.8; SD* *=* *19.0; *P *=* *0.007), physical role functioning with active controls (mean* *=* *42.2; SD* *=* *42.6 to mean* *=* *67.6; SD* *=* *35.8; *P *=* *0.001), non‐MBSR (mean* *=* *40.4; SD* *=* *41.5 to mean* *=* *59.6; SD* *=* *42.3; *P *=* *0.006), social functioning for active controls (mean* *=* *78.4; SD* *=* *25.9 to mean* *=* *84.8; SD* *=* *22.8; *P *=* *0.017), non‐MBSR (mean* *=* *72.1; SD* *=* *26.0 to mean* *=* *84.1; SD* *=* *25.3; *P *=* *0.001). A significant improvement between groups was reported in mental health for the MBSR group (*P *=* *0.001) and active controls (*P *=* *0.038) compared to non‐MBSR (Table [4](#cam41052-tbl-0004){ref-type="table-wrap"}).

Additional secondary outcome measures showed that MBSR participants reported improved coping capacity (*P *=* *0.028) versus non‐MBSR (Table [5](#cam41052-tbl-0005){ref-type="table-wrap"}).

Enhanced elements of mindfulness were shown regarding Nonreactivity within MBSR (mean* *=* *2.9; SD* *=* *0.7 to mean* *=* *3.3; SD* *=* *0.5; *P *\<* *0.001), and between groups compared to non‐MBSR (*P *=* *0.010), as well as on Observe both within MBSR group (mean* *=* *3.3; SD* *=* *0.7 to mean* *=* *3.6; SD* *=* *0.5; *P *\<* *0.001) and compared to non‐MBSR (*P *=* *0.006) (Table [6](#cam41052-tbl-0006){ref-type="table-wrap"}). Enriched posttraumatic growth was reported within MBSR (mean* *=* *59.78; SD* *=* *19.5 to mean* *=* *64.65; SD* *=* *17.7; *P *=* *0.005), and between groups for active controls versus non‐MBSR (*P *=* *0.049) (Table [7](#cam41052-tbl-0007){ref-type="table-wrap"}).

Biological response {#cam41052-sec-0021}
-------------------

Mean baseline NK‐cell activity increased significantly (mean* *=* *19.1; SD* *=* *8.2 to mean* *=* *22.0 SD* *=* *7.7; *P *=* *0.015) within the MBSR group. The absolute number of CD19^+^B‐lymphocytes increased (mean* *=* *0.15; SD* *=* *0.16 to mean* *=* *0.17; SD* *=* *0.15; *P *=* *0.004). The proportion of CD3^+^T‐lymphocytes decreased (mean = 72.8; SD = 11.1 to mean = 71.4; SD = 10.5; *P* = 0.027) as did that of CD3^+^8^+^T‐lymphocytes (mean* *=* *29.6; SD = 11.3 to mean = 28.4; SD = 10.5; *P* = 0.035), whereas the proportion of CD19^+^B‐lymphocytes increased (mean = 9.5; SD = 8.4 to mean = 11.6; SD = 7.6; *P* = 0.001). Analyses also demonstrated significant changes (*P *=* *0.041) between MBSR participants and non‐MBSR regarding decrease in the absolute number of NK cells (CD3‐16^+^56^+^NKx10e9/l).

There were also some significant changes pre and postintervention in active controls and in the non‐MBSR group suggesting a decrease in the absolute number of NK cells (CD3‐16‐56^+^NKx10e9/I) for active controls (*P *=* *0.011) compared to non‐MBSR. There were also significant changes for active controls regarding CD3‐16^+^56^+^NK% versus non‐MBSR (*P *=* *0.025) (Table [8](#cam41052-tbl-0008){ref-type="table-wrap"}). There were no significant differences in serum concentrations of IL‐6 or IL‐8 between any of the study groups.

Discussion {#cam41052-sec-0022}
==========

Our trial provides evidence in support of the efficacy of MBSR for psychological and biological response among women with breast cancer. The primary purpose of this study was to determine the efficacy of MBSR intervention on mood disorder, that is, depression and anxiety. Our finding of improvements in depression is consistent with other RTCs that have evaluated MBSR and mood disorders in breast cancer patients [21](#cam41052-bib-0021){ref-type="ref"}, [26](#cam41052-bib-0026){ref-type="ref"}. Unlike those studies, our findings revealed no significant changes in anxiety. However, consistent with our trial, a meta‐analysis of mindfulness‐based interventions that included participants who met the diagnostic criteria for a current episode of anxiety or depressive disorder show that MBSR is effective for reducing symptoms of depression, but not anxiety [65](#cam41052-bib-0065){ref-type="ref"}.

MBSR participants reported significantly greater improvements in symptoms, especially psychological symptoms. In addition, their symptom burden and distress significantly decreased. MBSR participants also improved in functional status; in line with previous research showing significant intergroup improvements in mental health [66](#cam41052-bib-0066){ref-type="ref"}, our findings indicate significant improved mental health between groups.

A common assumption is that mindfulness increases the individual\'s ability to cope, but few RCTs have examined the effect of MBSR on coping capacity. The MBSR intervention appears to improve coping effectiveness in breast cancer patients [32](#cam41052-bib-0032){ref-type="ref"}, and behavioral and cognitive coping [67](#cam41052-bib-0067){ref-type="ref"}. Results from our trial show that women who participated in the MBSR experienced improved coping capacity, here measured as sense of coherence (SOC). Previous research has identified SOC as a significant predictor of distress, number and type of coping strategies in women with breast cancer [68](#cam41052-bib-0068){ref-type="ref"}, suggesting the lower the SOC, the higher the levels of symptom burden [3](#cam41052-bib-0003){ref-type="ref"}. While Antonovsky [54](#cam41052-bib-0054){ref-type="ref"} believed that SOC is a relatively stable personality state, our findings show evidence that MBSR may influence SOC (i.e., to improve patients\' ability to manage, comprehend, and finding meaning living with breast cancer).

Enhanced elements of mindfulness were shown for non‐reactivity and observing in the MBSR group. Future research is needed to explore the complexity and relations among the different dimensions of mindfulness, and to gain a deeper understanding about which factors facilitate the cultivation of mindfulness [69](#cam41052-bib-0069){ref-type="ref"}.

Our trial indicates that the benefits of MBSR may also extend to posttraumatic growth. Relatively little research has investigated the relationship between posttraumatic growth and immunity. A study of patients with hepatoma suggests that higher PTGI scores are associated with higher peripheral blood leukocytes and longer survival [70](#cam41052-bib-0070){ref-type="ref"}. Further research addressing the interrelationship of MBSR with posttraumatic growth and immune response is warranted.

In terms of biological response, changes in NK‐cell activity and numbers of both NK cells and B cells within the MBSR group as well as between groups were seen. Of note was the finding that there were no changes in numbers of IL‐6 or IL‐8. The clinical relevance of these discrete findings is difficult to estimate and more research is needed to fully explain the clinical meaning of these biological parameters. However, consistent with our findings, there is intriguing evidence suggesting that finding meaning and personal growth is associated with T‐cell levels [71](#cam41052-bib-0071){ref-type="ref"} and NK‐cell activity [72](#cam41052-bib-0072){ref-type="ref"}. Furthermore, there have been prior reports that distress is associated with immune downregulation, including reduced NK‐cell activity [12](#cam41052-bib-0012){ref-type="ref"}, [32](#cam41052-bib-0032){ref-type="ref"}. In addition, participation in mindfulness training leads to a shift from proinflammatory response in cancer patients [33](#cam41052-bib-0033){ref-type="ref"} and a pilot study has suggested that improvements in well‐being following MBSR was associated with increased NK activity and decreased CRP levels [73](#cam41052-bib-0073){ref-type="ref"}.

Given the beneficial efficacy of MBSR on both psychological and biological outcomes, future longitudinal studies may be needed to investigate the effect of these outcomes on disease progression and survival. There were several tendencies in favor for MBSR group, although not statistically significant, and for some outcome variables statistically significant changes could be detected only within MBSR group but not between the groups. A larger sample size might have resulted in more significant differences between groups. Several improvements were also seen in active controls (i.e., physical and social role functioning, and observing) as well as between groups (i.e., global distress, mental health, and posttraumatic growth). Future research is needed to explore who benefits from participating in an MBSR intervention with weekly group sessions versus using a self‐instructing training program.

This study is characterized by several strengths, including use of active and non‐MBSR controls, random assignment, inclusion of patient‐reported outcomes and immune response among a homogenous group of women diagnosed with breast cancer. To our knowledge, this is the first MBSR intervention study to include a comparison between standardized MBSR and both active controls using a self‐instructing program and passive controls. The notable study limitation was that all women who fulfilled the inclusion criteria were invited without undergoing screened for mood disorder before study invitation. Furthermore, despite randomization, there were differences in distribution regarding disease stage (tumor size and type of breast cancer) which might have affected study results.

In conclusion, results from this RCT suggest that MBSR is beneficial and leads to psychological and biological improvements. MBSR may hold potential for alleviating depression, distress and symptom experience, and to strengthen coping capacity, which may improve breast cancer survivorship. Since there were also positive changes in the active control group, it is important to provide the self‐training program to patients who prefer to practice themselves, without weekly group exercises. Finally, longitudinal studies are required to investigate whether these positive psychological and biological responses remain constant, increases or decreases over time.

Conflict of Interest {#cam41052-sec-0024}
====================

The author(s) indicated no potential conflicts of interest.

Supporting information
======================

###### 

**Figure S1.** X. Typical result with dot plots showing CD3+, CD3+4+, CD3+8+, 19‐,and CD3‐16+56+ cells. Absolute numbers of cells were calculated using Trucount reference beads. Lymphocytes and Trucount beads were defined in a CD45 versus side scatter area (SSC‐A) and a CD19 versus SSC‐A plot, respectively. CD3+ and CD3‐ cells were then defined in a CD3 versus SSC‐A plot. Then CD3+4+ and CD3+8+ were defined in a plot of CD8 versus CD4. Finally CD19 and CD3‐16+56+ cells were defined in a plot of CD16+56+ versus CD19.

**Figure S2.** Y Typical result with dot plots showing regulatory T cells. Lymphocytes were defined in a forward scatter area (FSC‐A) versus side scatter area (SSC‐A) plot. CD3+4+ cells were then defined in a CD3 versus CD4 plot. Then CD3+4+25+ were defined in a plot of CD4 versus CD25. Finally CD3+4+25+FOXP3++ (regulatory T cells) cells were defined in a plot of CD25 versus FOXP3.

###### 

Click here for additional data file.
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